Back to today’s briefing

Story perspectives

New Dual Therapy Targets Resistant Ovarian Cancer Cells

12/11/2025

28 5

Summary

Story summary

Researchers at the University of Colorado Cancer Center test a therapy combining a PARP inhibitor with SM08502 for resistant ovarian cancer.
The Phase 1 trial aims to enhance effectiveness by attacking cancer from two angles.
The oral drugs may reduce risks linked to long-term PARP inhibitor use.
The study notes resistant cells activate WNT signaling, which the therapy indirectly targets.

1 of 1

Story summary

Researchers at the University of Colorado Cancer Center test a therapy combining a PARP inhibitor with SM08502 for resistant ovarian cancer.
The Phase 1 trial aims to enhance effectiveness by attacking cancer from two angles.
The oral drugs may reduce risks linked to long-term PARP inhibitor use.
The study notes resistant cells activate WNT signaling, which the therapy indirectly targets.